Non-Contact ultra-widefield angiography module

Article

Heidelberg Engineering is presenting a new, non-contact ultra-widefield angiography module for the SPECTRALIS and Heidelberg Retina Angiograph (HRA-2) product family…

Heidelberg Engineering is presenting a new, non-contact ultra-widefield angiography module for the SPECTRALIS and Heidelberg Retina Angiograph (HRA 2) product family.

The ultra-widefield angiography module consists of a dedicated lens and software. The lens attaches easily to the camera head and is interchangeable with the existing high resolution 30° and 55° widefield lenses. The non-contact ultra-widefield lens makes peripheral imaging convenient for both patient and operator. The confocal scanning laser ophthalmoscope (cSLO) technology and high quality refractive optics deliver high contrast, undistorted and evenly illuminated images out into the far periphery. High speed video angiography in ultra-widefield mode can be performed with both fluorescein and indocyanine green, individually or simultaneously.

The ultra-widefield module extends the range of applications and utility for existing Heidelberg Engineering cSLO devices while further improving patient workflow in practices and clinics. Ultra-widefield angiograms can be viewed with the proven Heidelberg Eye Explorer (HEYEX) software used by all Heidelberg Engineering devices. The new Heidelberg module provides a cost-effective alternative to standalone widefield imaging devices.

"Wide field imaging has becomes a 'crucial' need in modern retina care," said Prof. Giovanni Staurenghi, Chairman of the Eye Clinic at Sacco Hospital, Milan, Italy, in a recent press release.1 He added that "Many common diseases are underestimated due to the lack of peripheral angiography. The use of widefield fluorescein and indocyanine green angiography is possible today mainly with a contact lens. The recent development of a non-contact, ultra-widefield lens for the SPECTRALIS system adds a crucial tool to the armamentarium of retina specialists." Asked about key clinical applications for the new ultra-widefield angiography module, Prof. Staurenghi pointed at the "importance of ultra-widefield imaging in diabetic retinopathy where the visualization of all the retinal changes such as ischemia or retinal new vessels now becomes possible. In patients with uveitis ultra-widefield indocyanine green angiography is of particular interest."

Recent publications2,3,4 have confirmed the need for peripheral angiography to better manage patients with retinal vascular, degenerative and inflammatory diseases. Like other innovative imaging technologies such as spectral-domain OCT and BluePeak blue laser autofluorescence, the importance of ultra-widefield angiography is likely to grow in the near future. The addition of non-contact ultra-widefield imaging to the SPECTRALIS and HRA2 extends the functionality of the multi-modality imaging platform in an easy-to-use, cost-saving and comprehensive fashion.

First clinical images will be presented at the joint EURETINA and ESCRS meeting in Milan. Heidelberg Engineering plans to release the ultra-widefield angiography module for SPECTRALIS and HRA2 devices in 2013.

Booth number: N266
Website:www.HeidelbergEngineering.com

References

1. Heidelberg Engineering GmbH press release, August 24, 2012.
2. M.M. Wessel

et al.

, Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema,

Br. J. Ophthalmol.

, published online March 15, 2012.
3. P.S. Prasad,

Ophthalmology

, 2010;

117

:780–784.
4. J.P. Campbell, Wide-field Retinal Imaging in the Management of Noninfectious Posterior Uveitis,

Am. J. Ophthalmol.

, 2012, e-pub ahead of print.

Please note this product may not be FDA-approved for the US.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.